EICHOR
● Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Condition: Obesity · Sponsor: Boehringer Ingelheim
About this study
This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascular disease can participate. Participants must have previously tried to lose weight by changing their diet. The purpose of this study is to find out whether people with overweight or obesity who take a medicine called survodutide (BI 456906) are less or more likely to develop serious cardiovascular problems. It also aims to find out whether health parameters like blood pressure improve. Overweight and obesity are linked to cardiovascular disease. Survodutide is a medicine that is developed to help people with obesity or overweight to lose weight. Participants are divided into 3 groups of almost equal size. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under the skin once a week. All participants also receive counselling on diet and physical activity. Participants are in the study for up to 2 years and 3 months. During this time, it is planned that participants visit the study site up to 21 times and attend remote visits by video calls. During these visits, the doctors check participants' cardiovascular and o…
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (540)
| Cardiology P.C. | Birmingham, Alabama, United States | — |
| AMR Daphne | Daphne, Alabama, United States | — |
| AMR Mobile | Mobile, Alabama, United States | — |
| Mobile Heart Specialists, PC | Mobile, Alabama, United States | — |
| The Institute for Liver Health II DBA Arizona Clinical Trials | Chandler, Arizona, United States | — |
| Clinical Research Institute of Arizona, LLC | Sun City West, Arizona, United States | — |
| AMR Phoenix | Tempe, Arizona, United States | — |
| Arizona Liver Health-Tucson-67516 | Tucson, Arizona, United States | — |
| Yuma Clinical Trials | Yuma, Arizona, United States | — |
| Lynn Institute of the Ozarks | Little Rock, Arkansas, United States | — |
| Velocity Clinical Research-Huntington Park | Huntington Park, California, United States | — |
| Velocity Clinical Research, San Diego | La Mesa, California, United States | — |
+ 528 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06077864